{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:31:36Z","timestamp":1792697496573,"version":"4.5.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jtct.2025.06.025","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T12:16:56Z","timestamp":1750940216000},"page":"727-741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["American Society for Transplantation and Cellular Therapy Series #11: Updated Cytomegalovirus Guidelines in Hematopoietic Cell Transplant and Cellular Therapy Recipients"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4424-283X","authenticated-orcid":false,"given":"Fareed","family":"Khawaja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1318-2902","authenticated-orcid":false,"given":"Danniel","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8692-4145","authenticated-orcid":false,"given":"Michelle K.","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Hakki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breana K.","family":"Goscicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5691-5221","authenticated-orcid":false,"given":"Lara","family":"Danziger-Isakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7446-142X","authenticated-orcid":false,"given":"Andrew","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5021-0714","authenticated-orcid":false,"given":"Paul A.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1538-7984","authenticated-orcid":false,"given":"Michael","family":"Boeckh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2891-079X","authenticated-orcid":false,"given":"Genovefa A.","family":"Papanicolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeet S.","family":"Dadwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0277-3088","authenticated-orcid":false,"given":"Roy F.","family":"Chemaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jtct.2025.06.025_bib0001","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jtct.2020.10.004","article-title":"American Society for Transplantation and Cellular Therapy Infectious Disease Guidelines: preface to the series","volume":"27","author":"Carpenter","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"9","key":"10.1016\/j.jtct.2025.06.025_bib0002","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jtct.2021.05.001","article-title":"American Society for Transplantation and Cellular Therapy Series: #3-prevention of Cytomegalovirus infection and disease after hematopoietic cell Transplantation","volume":"27","author":"Hakki","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"12","key":"10.1016\/j.jtct.2025.06.025_bib0003","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jtct.2021.09.010","article-title":"American Society for Transplantation and Cellular Therapy Series: #4 - Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation","volume":"27","author":"Yong","year":"2021","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.jtct.2025.06.025_bib0004","doi-asserted-by":"crossref","unstructured":"Avery RK, Alain S, Alexander BD, et al. Maribavir for refractory Cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial clinical infectious diseases 2022;75(4):690-701. DOI: 10.1093\/cid\/ciab988.","DOI":"10.1093\/cid\/ciab988"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.025_bib0005","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13696","article-title":"Maribavir: mechanism of action, clinical, and translational science","volume":"17","author":"Sun","year":"2024","journal-title":"Clin Transl Sci"},{"issue":"6","key":"10.1016\/j.jtct.2025.06.025_bib0006","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/jac\/dkae094","article-title":"Absence of maribavir penetration into the central nervous system: confirmation by multiple cerebrospinal fluid dosages in a solid organ transplant recipient","volume":"79","author":"Luque-Paz","year":"2024","journal-title":"J Antimicrob Chemother"},{"issue":"20","key":"10.1016\/j.jtct.2025.06.025_bib0007","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.jtct.2025.06.025_bib0008","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1182\/blood-2013-05-499830","article-title":"CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT","volume":"122","author":"Schmidt-Hieber","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2025.06.025_bib0009","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1399-3046.2008.01084.x","article-title":"Cytomegalovirus infection in children who underwent hematopoietic stem cell transplantation at a single center: A retrospective study of the risk factors","volume":"13","author":"Yoon","year":"2009","journal-title":"Pediatr Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2025.06.025_bib0010","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1097\/00007890-199811270-00012","article-title":"Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients","volume":"66","author":"Ljungman","year":"1998","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.jtct.2025.06.025_bib0011","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.cmi.2024.03.001","article-title":"Mortality in recipients of allogeneic haematopoietic cell transplantation in the era of cytomegalovirus primary prophylaxis: a single-centre retrospective experience","volume":"30","author":"Febres-Aldana","year":"2024","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"10.1016\/j.jtct.2025.06.025_bib0012","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/ciab1064","article-title":"Impact of Letermovir primary Cytomegalovirus prophylaxis on 1-year mortality after allogeneic hematopoietic cell transplantation: A retrospective cohort study","volume":"75","author":"Su","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jtct.2025.06.025_bib0013","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/ejh.14251","article-title":"Impact of cytomegalovirus (CMV) seroconversion pre-allogeneic hematopoietic cell transplantation on posttransplant outcomes","volume":"113","author":"Sayyed","year":"2024","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.jtct.2025.06.025_bib0014","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/cid\/ciad550","article-title":"Revisiting Cytomegalovirus serology in allogeneic hematopoietic cell transplant recipients","volume":"78","author":"Portillo","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"17","key":"10.1016\/j.jtct.2025.06.025_bib0015","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1182\/bloodadvances.2023012234","article-title":"CMV reactivation during pretransplantation evaluation: a novel risk factor for posttransplantation CMV reactivation","volume":"8","author":"Zamora","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jtct.2025.06.025_bib0016","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/cid\/ciad709","article-title":"Treatment for first Cytomegalovirus infection post\u2013Hematopoietic cell transplant in the AURORA trial: A multicenter, double-blind, randomized, phase 3 trial comparing Maribavir with Valganciclovir","volume":"78","author":"Papanicolaou","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2025.06.025_bib0017","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiad293","article-title":"Comparative emergence of Maribavir and Ganciclovir resistance in a randomized phase 3 clinical trial for treatment of Cytomegalovirus infection","author":"Chou","year":"2024","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.jtct.2025.06.025_bib0018","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3026(23)00344-7","article-title":"Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Russo","year":"2024","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.jtct.2025.06.025_bib0019","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1083-8791(03)00287-8","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies","volume":"9","author":"Boeckh","year":"2003","journal-title":"Biol Blood Marrow Transpl"},{"issue":"Supplement_1","key":"10.1016\/j.jtct.2025.06.025_bib0020","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1093\/jpids\/piad059","article-title":"Current and emerging antiviral agents in the prevention and treatment of Cytomegalovirus in pediatric transplant recipients","volume":"13","author":"Valencia Deray","year":"2024","journal-title":"J Pediatr Infect Dis Soc"},{"issue":"5","key":"10.1016\/j.jtct.2025.06.025_bib0021","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.bbmt.2020.01.027","article-title":"Letermovir for secondary prophylaxis of Cytomegalovirus infection and disease after allogeneic hematopoietic cell transplantation: results from the French compassionate Program","volume":"26","author":"Robin","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"10.1016\/j.jtct.2025.06.025_bib0022","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/ejh.14258","article-title":"Letermovir as secondary prophylaxis of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: A single center experience","volume":"113","author":"Desai","year":"2024","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.jtct.2025.06.025_bib0023","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13187","article-title":"Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: real-world experience","volume":"21","author":"Lin","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jtct.2025.06.025_bib0024","article-title":"Letermovir for prevention of recurrent Cytomegalovirus in high-risk allogeneic hematopoietic cell transplantation recipients","author":"Han","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"7","key":"10.1016\/j.jtct.2025.06.025_bib0025","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/infdis\/jiz577","article-title":"Letermovir resistance analysis in a clinical trial of Cytomegalovirus prophylaxis for hematopoietic stem cell transplant recipients","volume":"221","author":"Douglas","year":"2020","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.jtct.2025.06.025_bib0026","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1111\/ajt.15764","article-title":"Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation","volume":"20","author":"Marty","year":"2020","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jtct.2025.06.025_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2017.10.019","article-title":"A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","volume":"148","author":"Chou","year":"2017","journal-title":"Antivir Res"},{"issue":"5","key":"10.1016\/j.jtct.2025.06.025_bib0028","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.bbmt.2020.01.015","article-title":"Features of Cytomegalovirus DNAemia blips in allogeneic hematopoietic stem cell transplant recipients: implications for optimization of preemptive antiviral therapy strategies","volume":"26","author":"Huntley","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2025.06.025_bib0029","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1111\/ajt.16450","article-title":"Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection","volume":"21","author":"Cassaniti","year":"2021","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jtct.2025.06.025_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105299","article-title":"Reliable quantification of Cytomegalovirus DNAemia in Letermovir treated patients","volume":"201","author":"Weinberger","year":"2022","journal-title":"Antivir Res"},{"issue":"2","key":"10.1016\/j.jtct.2025.06.025_bib0031","doi-asserted-by":"crossref","first-page":"G","DOI":"10.1111\/tid.14021","article-title":"Features of cytomegalovirus DNAemia and virus-specific T-cell responses in allogeneic hematopoietic stem-cell transplant recipients during prophylaxis with letermovir","volume":"25","author":"Gim\u00e9nez","year":"2023","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.025_bib0032","doi-asserted-by":"crossref","DOI":"10.4084\/MJHID.2024.039","article-title":"Letermovir primary Cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients: real-life data from a university hospital in Argentina","volume":"16","author":"Herrera","year":"2024","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"3","key":"10.1016\/j.jtct.2025.06.025_bib0033","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/cid\/ciae321","article-title":"Consensus definitions of Cytomegalovirus (CMV) infection and disease in Transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from the Transplant Associated Virus Infections Forum","volume":"79","author":"Ljungman","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.jtct.2025.06.025_bib0034","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/infdis\/jix048","article-title":"Cytomegalovirus (CMV) DNA quantitation in bronchoalveolar lavage fluid from hematopoietic stem cell transplant recipients with CMV pneumonia","volume":"215","author":"Boeckh","year":"2017","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.jtct.2025.06.025_bib0035","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/cid\/ciy706","article-title":"Maribavir for refractory or resistant Cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: A randomized, dose-ranging, double-blind, phase 2 study","volume":"68","author":"Papanicolaou","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jtct.2025.06.025_bib0036","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.antiviral.2012.05.013","article-title":"Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo","volume":"95","author":"Chou","year":"2012","journal-title":"Antivir Res"},{"issue":"8","key":"10.1016\/j.jtct.2025.06.025_bib0037","doi-asserted-by":"crossref","first-page":"ofae422","DOI":"10.1093\/ofid\/ofae422","article-title":"Cytomegaloviral infections in recipients of chimeric antigen receptor T-cell therapy: an observational study with focus on oncologic outcomes","volume":"11","author":"Khawaja","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.jtct.2025.06.025_bib0038","article-title":"Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies","volume":"25","author":"Kampouri","year":"2023","journal-title":"Transpl Infect Dis"},{"issue":"14","key":"10.1016\/j.jtct.2025.06.025_bib0039","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1182\/bloodadvances.2024012922","article-title":"Incidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy","volume":"8","author":"Lin","year":"2024","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.jtct.2025.06.025_bib0040","doi-asserted-by":"crossref","first-page":"851.e1","DOI":"10.1016\/j.jtct.2022.09.007","article-title":"Impact of Cytomegalovirus replication in patients with aggressive B cell lymphoma treated with chimeric antigen receptor T cell therapy","volume":"28","author":"M\u00e1rquez-Algaba","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"3","key":"10.1016\/j.jtct.2025.06.025_bib0041","article-title":"Post-CD19 chimeric antigen receptor T-cell therapy Cytomegalovirus retinitis","volume":"14","author":"Bin Dokhi","year":"2022","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.jtct.2025.06.025_bib0042","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3324\/haematol.2022.281719","article-title":"Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant","volume":"108","author":"Chen","year":"2023","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.jtct.2025.06.025_bib0043","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jtct.2024.07.018","article-title":"Best practice considerations by The American Society of Transplant and Cellular Therapy: infection prevention and management after chimeric antigen receptor T cell Therapy for hematological malignancies","volume":"30","author":"Shahid","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"4","key":"10.1016\/j.jtct.2025.06.025_bib0044","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/cid\/ciad708","article-title":"Cytomegalovirus (CMV) reactivation and CMV-specific cell-mediated immunity after chimeric antigen receptor T-cell therapy","volume":"78","author":"Kampouri","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"Supplement_1","key":"10.1016\/j.jtct.2025.06.025_bib0045","doi-asserted-by":"crossref","first-page":"S557","DOI":"10.1093\/ofid\/ofab466.1125","article-title":"930. Clinically significant CMV infections in patients with lymphoma or multiple myeloma","volume":"8","author":"Sassine","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"8900","key":"10.1016\/j.jtct.2025.06.025_bib0046","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0140-6736(94)91835-X","article-title":"Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation","volume":"343","author":"Prentice","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2025.06.025_bib0047","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.1039938","article-title":"Prevention and management of human cytomegalovirus in pediatric HSCT recipients: A review","volume":"10","author":"Hiskey","year":"2022","journal-title":"Front Pediatr"},{"issue":"suppl_2","key":"10.1016\/j.jtct.2025.06.025_bib0048","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1093\/jpids\/piy104","article-title":"Cytomegalovirus in pediatric hematopoietic stem cell transplantation: A case-based panel discussion of current challenges","volume":"7","author":"Danziger-Isakov","year":"2018","journal-title":"J Pediatr Infect Dis Soc"},{"issue":"3","key":"10.1016\/j.jtct.2025.06.025_bib0049","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/INF.0000000000004208","article-title":"Pharmacokinetics, safety, and efficacy of Letermovir for Cytomegalovirus prophylaxis in adolescent hematopoietic cell transplantation recipients","volume":"43","author":"Groll","year":"2024","journal-title":"Pediatr Infect Dis J"},{"issue":"Suppl 2","key":"10.1016\/j.jtct.2025.06.025_bib0050","article-title":"2563. Cytomegalovirus (CMV) prophylaxis with Letermovir (LET) in pediatric (Birth to < 18 years of age) allogeneic hematopoietic cell transplant (HCT) recipients: pharmacokinetics (PK), safety and efficacy results of a phase 2b study","volume":"10","author":"Schulte","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jtct.2025.06.025_bib0051","doi-asserted-by":"crossref","DOI":"10.1111\/tid.70006","article-title":"Efficacy and safety of Letermovir for Cytomegalovirus prophylaxis in pediatric hematopoietic stem cell transplantation recipients: A systematic review, meta-analysis, and meta-regression","author":"Aldalati","year":"2025","journal-title":"Transpl Infect Dis"},{"issue":"8","key":"10.1016\/j.jtct.2025.06.025_bib0052","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/s41409-024-02315-1","article-title":"Letermovir as cytomegalovirus prophylaxis in children undergoing allogeneic hematopoietic cell transplantation","volume":"59","author":"Pfeiffer","year":"2024","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"10.1016\/j.jtct.2025.06.025_bib0053","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41409-024-02209-2","article-title":"Letermovir for Cytomegalovirus infection in pediatric patients undergoing allogenic hematopoietic stem cell transplantation: a real-life study by the Infectious Diseases Working Group of Italian Association of Pediatric Hematology-Oncology (AIEOP)","volume":"59","author":"Galaverna","year":"2024","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.025_bib0054","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s10875-023-01617-1","article-title":"Letermovir for CMV prophylaxis in very high-risk pediatric hematopoietic stem cell transplantation recipients for inborn errors of immunity","volume":"44","author":"C\u00e9sar","year":"2023","journal-title":"J Clin Immunol"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.025_bib0055","doi-asserted-by":"crossref","first-page":"62.e1","DOI":"10.1016\/j.jtct.2022.10.005","article-title":"Letermovir as Cytomegalovirus prophylaxis in a pediatric cohort: A retrospective analysis","volume":"29","author":"Kuhn","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"7","key":"10.1016\/j.jtct.2025.06.025_bib0056","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.21873\/anticanres.15848","article-title":"Letermovir prophylaxis for Cytomegalovirus infection in children after hematopoietic cell transplantation","volume":"42","author":"Richert-Przygonska","year":"2022","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jtct.2025.06.025_bib0057","unstructured":"INSTRUCTIONS FOR USE: LETERMOVIR ORAL PELLETS. https:\/\/www.merck.com\/product\/usa\/pi_circulars\/p\/prevymis\/prevymis_ifu.pdf. Accessed May 5, 2025."},{"issue":"16","key":"10.1016\/j.jtct.2025.06.025_bib0058","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/bloodadvances.2018016493","article-title":"Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation","volume":"2","author":"Chen","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.025_bib0059","doi-asserted-by":"crossref","DOI":"10.1111\/petr.14580","article-title":"Pharmacokinetic analysis driven letermovir dosing in pediatric hematopoietic cell transplantation patients with resistant CMV disease","volume":"28","author":"Pai","year":"2024","journal-title":"Pediatr Transpl"},{"issue":"3","key":"10.1016\/j.jtct.2025.06.025_bib0060","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s40121-021-00452-4","article-title":"Cytomegalovirus infection and the implications of drug-resistant mutations in pediatric allogeneic hematopoietic stem cell transplant recipients: A retrospective study from a tertiary hospital in China","volume":"10","author":"Yu","year":"2021","journal-title":"Infect Dis Ther"},{"issue":"6","key":"10.1016\/j.jtct.2025.06.025_bib0061","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/tid.12311","article-title":"The impact of drug-resistant cytomegalovirus in pediatric allogeneic hematopoietic cell transplant recipients: a prospective monitoring of UL97 and UL54 gene mutations","volume":"16","author":"Choi","year":"2014","journal-title":"Transpl Infect Dis"},{"issue":"6","key":"10.1016\/j.jtct.2025.06.025_bib0062","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1399-3062.2012.00760.x","article-title":"Cytomegalovirus infection and ganciclovir resistance caused by UL97 mutations in pediatric transplant recipients","volume":"14","author":"Kim","year":"2012","journal-title":"Transpl Infect Dis"},{"issue":"5","key":"10.1016\/j.jtct.2025.06.025_bib0063","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/psp4.12943","article-title":"Population pharmacokinetic modeling and simulation of maribavir to support dose selection and regulatory approval in adolescents with posttransplant refractory cytomegalovirus","volume":"12","author":"Sun","year":"2023","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"3","key":"10.1016\/j.jtct.2025.06.025_bib0064","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.1097\/MPH.0000000000002841","article-title":"Use of Maribavir for multidrug resistant cytomegaloviremia in a pediatric oncology patient","volume":"46","author":"Fisher","year":"2024","journal-title":"J Pediatr Hematol Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2025.06.025_bib0065","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14290","article-title":"Dynamics of cytomegalovirus-specific T-cell recovery in allogeneic hematopoietic cell transplant recipients using a commercially available flow cytometry assay: A pilot study","volume":"26","author":"Jacobs","year":"2024","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jtct.2025.06.025_bib0066","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2024.12720","article-title":"In vitro profiling of commonly used post-transplant immunosuppressants reveals distinct impact on antiviral T-cell immunity towards CMV","volume":"37","author":"Krueger","year":"2024","journal-title":"Transpl Int"},{"issue":"8","key":"10.1016\/j.jtct.2025.06.025_bib0067","doi-asserted-by":"crossref","first-page":"ofad386","DOI":"10.1093\/ofid\/ofad386","article-title":"Impact of baseline and Week 2 and week 4 posttransplant CMV cell-mediated immunity on risk of CMV infections and mortality in recipients of allogeneic hematopoietic cell transplant","volume":"10","author":"Ariza-Heredia","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"10.1016\/j.jtct.2025.06.025_bib0068","doi-asserted-by":"crossref","first-page":"392.e1","DOI":"10.1016\/j.jtct.2023.03.018","article-title":"Immunologic monitoring after allogeneic stem cell transplantation: T-SPOT.CMV and QuantiFERON-CMV, are they the same?","volume":"29","author":"Callens","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"2","key":"10.1016\/j.jtct.2025.06.025_bib0069","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246191","article-title":"Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients","volume":"16","author":"Seo","year":"2021","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.jtct.2025.06.025_bib0070","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1093\/cid\/ciz1210","article-title":"Cytomegalovirus (CMV) cell-mediated immunity and CMV infection after allogeneic hematopoietic cell transplantation: the REACT study","volume":"71","author":"Chemaly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2025.06.025_bib0071","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-025-02611-4","article-title":"ELISPOT as a predictor of clinically significant cytomegalovirus infection after hematopoietic cell transplantation in letermovir recipients","author":"Zamora","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.06.025_bib0072","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3324\/haematol.2019.229252","article-title":"Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation","volume":"106","author":"Wagner-Drouet","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2025.06.025_bib0073","article-title":"Cell-mediated immunity to guide primary prophylaxis for CMV infection in organ transplant recipients: A multicenter single-arm prospective study","author":"Solera","year":"2024","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.025_bib0074","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.2020009396","article-title":"Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation","volume":"138","author":"Zamora","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2025.06.025_bib0075","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/cid\/ciab298","article-title":"Refractory and resistant Cytomegalovirus after hematopoietic cell transplant in the Letermovir primary prophylaxis era","volume":"73","author":"Sassine","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jtct.2025.06.025_bib0076","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28733","article-title":"Comparison of intracellular cytokine staining versus an ELISA-based assay to assess CMV-specific cell-mediated immunity in high-risk kidney transplant recipients","volume":"95","author":"Fern\u00e1ndez-Ruiz","year":"2023","journal-title":"J Med Virol"},{"issue":"8","key":"10.1016\/j.jtct.2025.06.025_bib0077","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1177\/10600280231207899","article-title":"Real-world experience with CMV inSIGHT T cell immunity testing in high-risk kidney and pancreas transplant recipients","volume":"58","author":"Descourouez","year":"2024","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jtct.2025.06.025_bib0078","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2217\/fmb-2019-0288","article-title":"Brincidofovir: understanding its unique profile and potential role against adenovirus and other viral infections","volume":"15","author":"Alvarez-Cardona","year":"2020","journal-title":"Future Microbiol"},{"issue":"6","key":"10.1016\/j.jtct.2025.06.025_bib0079","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1097\/MPH.0000000000001227","article-title":"Brincidofovir (CMX001) toxicity associated with epithelial apoptosis and crypt drop out in a hematopoietic cell transplant patient: challenges in distinguishing drug toxicity from GVHD","volume":"40","author":"Detweiler","year":"2018","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2025.06.025_bib0080","first-page":"S89","article-title":"Preliminary results of a phase 2a clinical trial to evaluate safety, tolerability and antiviral activity of intravenous brincidofovir (BCV IV) in immunocompromised patients with Adenovirus infection","volume":"30","author":"Grimley","year":"2024","journal-title":"Transplant Cell Ther Off Publ Am Soc Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2025.06.025_bib0081","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100787","article-title":"A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients","volume":"33","author":"Ljungman","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"5","key":"10.1016\/j.jtct.2025.06.025_bib0082","doi-asserted-by":"crossref","first-page":"306","DOI":"10.7326\/M19-2511","article-title":"Poxvirus vectored Cytomegalovirus vaccine to prevent Cytomegalovirus viremia in transplant recipients: A phase 2, randomized clinical trial","volume":"172","author":"Aldoss","year":"2020","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.jtct.2025.06.025_bib0083","first-page":"1994","article-title":"A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopoietic stem cell transplant","volume":"109","author":"Nakamura","year":"2024","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.jtct.2025.06.025_bib0084","doi-asserted-by":"crossref","first-page":"e668","DOI":"10.1093\/infdis\/jiae114","article-title":"Safety and immunogenicity of a messenger RNA-based Cytomegalovirus vaccine in healthy adults: results from a phase 1 randomized clinical trial","volume":"230","author":"Fierro","year":"2024","journal-title":"J Infect Dis"},{"issue":"23","key":"10.1016\/j.jtct.2025.06.025_bib0085","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00747-19","article-title":"A replication-defective Human Cytomegalovirus vaccine elicits humoral immune responses analogous to those with natural infection","volume":"93","author":"Liu","year":"2019","journal-title":"J Virol"},{"issue":"50","key":"10.1016\/j.jtct.2025.06.025_bib0086","doi-asserted-by":"crossref","first-page":"7437","DOI":"10.1016\/j.vaccine.2018.02.089","article-title":"Vaccination against the human cytomegalovirus","volume":"37","author":"Plotkin","year":"2019","journal-title":"Vaccine"},{"issue":"362","key":"10.1016\/j.jtct.2025.06.025_bib0087","doi-asserted-by":"crossref","first-page":"362ra145","DOI":"10.1126\/scitranslmed.aaf9387","article-title":"A replication-defective human cytomegalovirus vaccine for prevention of congenital infection","volume":"8","author":"Wang","year":"2016","journal-title":"Sci Transl Med"},{"issue":"19","key":"10.1016\/j.jtct.2025.06.025_bib0088","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01012-18","article-title":"Multiantigenic modified vaccinia virus Ankara vaccine vectors to elicit potent humoral and cellular immune reponses against Human Cytomegalovirus in mice","volume":"92","author":"Chiuppesi","year":"2018","journal-title":"J Virol"},{"issue":"10","key":"10.1016\/j.jtct.2025.06.025_bib0089","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1128\/AAC.01623-15","article-title":"Rapid In vitro evolution of Human Cytomegalovirus UL56 mutations that confer letermovir resistance","volume":"59","author":"Chou","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.jtct.2025.06.025_bib0090","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/QCO.0000000000001065","article-title":"The emergence of letermovir and maribavir drug-resistant mutations: from clinical trials to real-world studies","volume":"37","author":"Zhu","year":"2024","journal-title":"Curr Opin Infect Dis"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.025_bib0091","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/infdis\/170.1.189","article-title":"Randomized phase I trial of two different combination foscarnet and ganciclovir chronic maintenance therapy regimens for AIDS patients with cytomegalovirus retinitis: AIDS clinical Trials Group Protocol 151","volume":"170","author":"Jacobson","year":"1994","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.jtct.2025.06.025_bib0092","doi-asserted-by":"crossref","first-page":"e248","DOI":"10.1097\/TP.0000000000003260","article-title":"Combination treatment with Letermovir and Ganciclovir for maintenance therapy of multidrug-resistant CMV infection in a liver transplant recipient","volume":"104","author":"Kronig","year":"2020","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.jtct.2025.06.025_bib0093","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9081666","article-title":"Combined therapy with intravenous immunoglobulins, Letermovir and (Val-)Ganciclovir in complicated courses of CMV-infection in transplant recipients","volume":"9","author":"Di Cristanziano","year":"2021","journal-title":"Microorganisms"},{"issue":"4","key":"10.1016\/j.jtct.2025.06.025_bib0094","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13693","article-title":"The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients","volume":"23","author":"Jorgenson","year":"2021","journal-title":"Transpl Infect Dis"},{"issue":"11","key":"10.1016\/j.jtct.2025.06.025_bib0095","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14401","article-title":"Use of letermovir-valganciclovir combination as a step-down treatment after foscarnet for ganciclovir-resistant CMV infection in kidney transplant recipients","volume":"35","author":"Rho","year":"2021","journal-title":"Clin Transpl"},{"issue":"10","key":"10.1016\/j.jtct.2025.06.025_bib0096","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1128\/AAC.00577-06","article-title":"Maribavir antagonizes the antiviral action of Ganciclovir on Human Cytomegalovirus","volume":"50","author":"Chou","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jtct.2025.06.025_bib0097","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.antiviral.2018.08.015","article-title":"In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus","volume":"158","author":"O'Brien","year":"2018","journal-title":"Antivir Res"},{"key":"10.1016\/j.jtct.2025.06.025_bib0098","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14444","article-title":"Real-world experience with Maribavir for treatment of refractory or resistant Cytomegalovirus infection in hematopoietic cell transplant recipients and hematologic malignancy patients","author":"Daher","year":"2025","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jtct.2025.06.025_bib0099","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.antiviral.2018.07.013","article-title":"Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus","volume":"157","author":"Chou","year":"2018","journal-title":"Antivir Res"},{"issue":"5","key":"10.1016\/j.jtct.2025.06.025_bib0100","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/jcpt.13585","article-title":"Letermovir and maribavir for pan-resistant cytomegalovirus infection in a patient with haematologic malignancy: consideration for combination therapy","volume":"47","author":"Dickter","year":"2022","journal-title":"J Clin Pharm Ther"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725012680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725012680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T23:57:02Z","timestamp":1759881422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725012680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":100,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2666636725012680"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.06.025","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"American Society for Transplantation and Cellular Therapy Series #11: Updated Cytomegalovirus Guidelines in Hematopoietic Cell Transplant and Cellular Therapy Recipients","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.06.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}